Navigation Links
Arthritis drug might prove effective in fighting the flu, study suggests
Date:5/26/2009

Researchers at the University of Maryland School of Medicine have found that an approved drug for treating rheumatoid arthritis reduces severe illness and death in mice exposed to the Influenza A virus. Their findings suggest that tempering the response of the body's immune system to influenza infection may alleviate some of the more severe symptoms and even reduce mortality from this virus.

The scientists report in the June 1 edition of The Journal of Immunology, which is now available online, that mice infected with the Influenza A virus responded favorably to a drug called Abatacept, which is commonly used to treat people with rheumatoid arthritis. The mice had been given "memory" T-cells, or white blood cells that have been primed to fight the invading virus as the result of previous exposure to Influenza A.

"We found that treating the mice with Abatacept minimized tissue damage caused by the immune response, but still enabled the body to rid itself of the virus. The mice didn't become as sick, recovered much faster and had much less damage to the lungs, compared to mice that weren't given the drug," says Donna L. Farber, Ph.D., a professor of surgery and microbiology and immunology at the University of Maryland School of Medicine and the study's senior author.

"Moreover, treatment with Abatacept significantly improved survival for mice infected with a lethal dose of influenza virus," Dr. Farber says. "The survival rate for the treated mice was 80 percent, compared to 50 percent for the mice that weren't treated."

She explains that the drug does not interrupt the immune system's early, rapid attack in the lungs, which helps to kill the virus, but it prevents "memory" T-cells from overreacting, which produces multiple negative effects. "It's this overactive immune response that can make you feel sick and can also lead to pneumonia," she says.

The study's lead author, John R. Teijaro, a researcher in Dr.
'/>"/>

Contact: Karen Warmkessel
kwarmkessel@umm.edu
410-328-8919
University of Maryland Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Using coxibs and NSAIDs to treat osteoarthritis
2. Biologic treatment for rheumatoid arthritis and the risk of cancer
3. Knee arthritis link to lung cancer
4. Genes Boost Risk for Rheumatoid Arthritis, Lupus
5. The genes involved in rheumatoid arthritis identified
6. Empowerment Program Gets Patients on the PATH to Managing the Physical and Emotional Effects of Psoriatic Arthritis
7. Genome Area Linked to Rheumatoid Arthritis
8. Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis
9. Meditation therapy for rheumatoid arthritis patients
10. Meditation May Help Rheumatoid Arthritis Sufferers
11. Researchers identify genes that increase rheumatoid arthritis risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... hormone therapy has spawned a prevalent but preventable side ... flashes, according to a study by a Yale School ... study published in the Aug. 27 online issue of ... moderate to severe hot flashes also called vasomotor ... Women with VMS experience more than feeling hot; other ...
(Date:8/27/2014)... (PDT, which uses topical agents and light to kill ... common skin lesion caused by sun damage) at three ... to freeze lesions). , Author: Gayatri Patel, ... Center, in Sacramento, and colleagues. , Background: ... found on individuals with fair complexions who have had ...
(Date:8/27/2014)... Warren, MI (PRWEB) August 27, 2014 Michigan ... to help the children of a local elementary school by ... year. Siersma Elementary School has year-round attendance, and Michigan Head ... equipped to meet the new school year. , "There are ... think this is a great way to give back to ...
(Date:8/27/2014)... 2014 Dr. Stewart Shofner ... multitudes of patients suffering from impaired vision. Some of ... vision correction surgery . Recently, Dr. Shofner has noticed ... an eye exam and also online. To help patients ... myths about glaucoma. , 1)    Myth: People with perfect vision ...
(Date:8/27/2014)... Washington, New York (PRWEB) August 27, 2014 ... dedicated to protecting the rights of victims injured by ... new rules in place for discovery procedures, specifically Collection ... brought over C.R. Bard’s transvaginal mesh devices. (MDL No. ... Products Liability Litigation, the United States District Court, Southern ...
Breaking Medicine News(10 mins):Health News:The high cost of hot flashes: Millions in lost wages preventable 2Health News:Photodynamic therapy vs. cryotherapy for actinic keratoses 2Health News:Michigan Head & Neck Institute is Conducting Their 2nd Annual School Supplies Drive at Their Facility to Benefit Local Year-Round Elementary School Students 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 4Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 2Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 3Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 4
... for Gerontology in Higher Education (AGHE) the educational ... will hold its 37th Annual Meeting and Educational Leadership ... Hilton Cincinnati Netherland Plaza in Cincinnati, OH. Media ... This conference provides a forum for professionals in the field ...
... , THURSDAY, Feb. 24 (HealthDay News) -- Fewer men ... (PSA) screening for prostate cancer since the release of guidelines ... few years ago, say researchers. This study examined ... decline in PSA screening was three percent among men aged ...
... University of Maryland-led team of scientists indicate that a ... antibody or a scorpion anti-malarial toxin could be ... combating malaria, at a time when the effectiveness of ... a study published in the February 25 issue of ...
... Administration and Georgetown University Medical Center (GUMC) today announced ... ethics, education, and training. The partnership enhances the capabilities ... improving public health. "We are excited about this ... goal of translating basic research discoveries into real world ...
... By Randy Dotinga HealthDay Reporter , THURSDAY, Feb. ... the immune systems of HIV patients and may stave off ... to recommend the drug for this purpose, the findings of ... drugs that can help adjust the immune response in HIV ...
... donor-liver distribution network developed by University of Pittsburgh researchers ... receiving the transplants they need. The team reports ... donor livers currently are doled out to 11 national ... demographics, an arrangement that prevents many livers from getting ...
Cached Medicine News:Health News:As America's senior population grows, meeting to outline effective education about aging 2Health News:PSA Screening for Prostate Cancer Dips in Large U.S. Health Network 2Health News:New study shows ability of transgenic fungi to combat malaria and other bug-borne diseases 2Health News:New study shows ability of transgenic fungi to combat malaria and other bug-borne diseases 3Health News:New study shows ability of transgenic fungi to combat malaria and other bug-borne diseases 4Health News:FDA and Georgetown University Medical Center announce partnership 2Health News:Statins Might Help HIV Patients, Study Suggests 2Health News:Redesign of US donor-liver network could boost transplants by several hundred per year 2Health News:Redesign of US donor-liver network could boost transplants by several hundred per year 3
(Date:8/27/2014)... , Aug. 27, 2014 IRIDEX Corporation (NASDAQ: ... James H. Mackaness is scheduled to make an investor ... at 2:55 p.m. Eastern Time on Wednesday, September 3, in ... of the investor presentation will be available in the Investors ... About IRIDEX IRIDEX Corporation was founded ...
(Date:8/27/2014)... Pa. , Aug. 27, 2014   Auxilium Pharmaceuticals ... integrated specialty biopharmaceutical company, today announced that certain members ... Morgan Stanley Healthcare Conference to be held September 8-10, ... Adrian Adams , Chief Executive Officer and President, is ... its product portfolio at 10:55 a.m. ET on Wednesday, ...
(Date:8/27/2014)... Asterias Biotherapeutics Inc. (OTCBB: ASTY) has received ... to initiate a Phase 1/2a clinical trial of its ... injury.  The approved trial follows the successful completion of ... is designed to assess safety and activity of escalating ... cord injuries, the first targeted indication for AST-OPC1 and ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5
... IRVINE, Calif., Aug. 11, 2011 ChromaDex Corporation ... provides proprietary, science-based solutions and ingredients to the ... industries, today announced financial results for the second ... calculated in accordance with U.S. Generally Accepted Accounting ...
... 2011 Reportlinker.com announces that a ... available in its catalogue: ... - Global Opportunity Assessment, Competitive ... 2017 ...
Cached Medicine Technology:ChromaDex Announces Financial Results for Second Quarter 2011 2ChromaDex Announces Financial Results for Second Quarter 2011 3ChromaDex Announces Financial Results for Second Quarter 2011 4Disposable Hospital Supplies - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2017 2Disposable Hospital Supplies - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2017 3Disposable Hospital Supplies - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2017 4Disposable Hospital Supplies - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2017 5Disposable Hospital Supplies - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2017 6Disposable Hospital Supplies - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2017 7Disposable Hospital Supplies - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2017 8Disposable Hospital Supplies - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2017 9Disposable Hospital Supplies - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2017 10
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: